Elsevier

Atherosclerosis

Volume 154, Issue 3, 15 February 2001, Pages 739-746
Atherosclerosis

A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study

https://doi.org/10.1016/S0021-9150(00)00623-7Get rights and content

Abstract

Increased iron stores may play a role in the development of coronary heart disease (CHD) by increasing lipoprotein oxidation. Recently, mutations have been discovered in the gene (HFE) for hereditary hemochromatosis, an autosomal recessive condition of disordered iron metabolism, absorption, and storage. It is possible that people who carry HFE mutations have increased risk of CHD. We used a prospective case-cohort design (243 CHD cases and 535 non-cases) to determine whether the HFE C282Y mutation was associated with incident CHD in a population-based sample of middle-aged men and women. The frequencies of homozygosity and heterozygosity for the C282Y mutation in the ARIC study population were 0.2% (one homozygous person) and 6%, respectively. The C282Y mutation was associated with nonsignificantly increased risk of CHD (relative risk=1.60, 95% CI 0.9–2.9). After adjusting for other confounding risk factors (age, race, gender, ARIC community, smoking status, diabetes status, hypertension status, LDL cholesterol, HDL cholesterol, and triglycerides), the association became stronger (relative risk=2.70, 95% CI 1.2–6.1). However, a sensitivity analysis showed that this estimate of relative risk was somewhat unstable due to few subjects in some strata. Our prospective findings suggest that individuals carrying the HFE C282Y mutation may be at increased risk of CHD.

Introduction

Coronary heart disease (CHD) has a multifactorial etiology with both genetic and nongenetic causes. Sullivan hypothesized that the sex difference in CHD is due to iron excess in men and postmenopausal women compared to premenopausal women [1]. A prospective study by Salonen and colleagues [2], [3] in Eastern Finnish men suggested high serum ferritin, a marker of iron excess, is associated with increased risk of CHD. However, the majority of prospective epidemiologic research found no association between serum ferritin [4], [5], [6], [7], or other measures of iron level [4], [8], [9], [10], [11], [12], [13], [14], and CHD. In the ARIC study, there was no association between serum ferritin levels and carotid wall thickness [15].

Iron is thought to catalyze the formation of free radicals [16], [17], [18], [19], [20] and convert poorly reactive radicals (e.g. hydrogen peroxide) into highly reactive ones (e.g. the hydroxyl radical). The hydroxyl radical can initiate lipid peroxidation, causing LDL to undergo an oxidative modification that targets it for uptake by macrophages [20], [21], [22]. These macrophages form lipid rich foam cells in the endothelium of arteries, leading to the development of fatty streaks, the precursor to atherosclerotic plaques. It is also believed that free radicals may damage arterial endothelium directly [23] and interfere with normal vasomotor regulation [24].

Hereditary hemochromatosis, a relatively common autosomal recessive condition, is a disease of disordered iron metabolism causing the body to absorb and store excess iron. In 1996, Feder and colleagues [25] identified and cloned a gene for hemochromatosis at the HLA locus termed HFE. Amino acid substitutions caused by two missense mutations Cys282Tyr (C282Y) and His63Asp (H63D) in the gene have been reported [25]. The C282Y mutation, which causes a substitution of a tyrosine for a cysteine, provides a more consistent association with the disease across studies [26], [27], [28], [29], [30], [31] and has a higher penetrance than H63D [32]. Compound heterozygosity for C282Y and H63D is associated with increased hemochromatosis risk. Depending on ethnic backgrounds, the frequencies of homozygosity and heterozygosity for the C282Y mutation are ≈0–1% and 2–14%, respectively [33].

Tissue damage from iron overload in homozygous hemochromatosis results in various clinical manifestations including cirrhosis, cardiomyopathy, diabetes, skin pigmentation and various cancers [33], [34]. Heterozygosity for the C282Y mutation could increase risk of CHD by increasing iron stores and lipid oxidation. To date, two studies have suggested that heterozygosity for the C282Y mutation is associated with CHD [35], [36], and four have not [30], [37], [38], [39]. The objective of this study was to determine if there is an association between the presence of the C282Y mutation of the HFE gene and incident CHD in a population-based cohort study.

Section snippets

Study population

Between 1987 and 1989, the ARIC Study recruited a cohort totalling 15 792 persons aged 45–64 years. Population samples were selected by probability sampling of Forsyth County, North Carolina; Jackson, Mississippi (black people only); the northwest suburbs of Minneapolis, Minnesota; and Washington County, Maryland. Participants underwent reexamination in 1990 through 1992 (93% return rate), in 1993 through 1995 (86% return rate), and in 1996 through 1998 (80% return rate).

Baseline measurements

After an 8-h fasting

Sample characteristics

The sample included 243 incident CHD cases (157 definite or probable MI, 20 silent MI, 26 definite fatal CHD, and 40 revascularization procedure) and a reference cohort sample of 535. Due to the case-cohort design, 10 individuals in the reference cohort sample eventually became CHD cases. Approximately 25% of the CHD cases were black, and 72% were men.

Based on the cohort random sample, we estimated that the frequency of homozygosity for the C282Y mutation in the entire ARIC population was 0.2%

Discussion

In this prospective study, we found that individuals who carried the HFE C282Y mutation may be at greater risk of developing CHD than those without the mutation. The crude association was positive but relatively weak (RR=1.60) and not statistically significant. After adjusting for confounding variables the association became very strong (RR=2.70). This was explained by the surprising fact that C282Y carriers had lower CHD risk factors than non-carriers: less diabetes, less smoking, lower LDL

Acknowledgements

The ARIC Study was funded by contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022 from the US National Heart, Lung, and Blood Institute. The authors thank the ARIC participants and staff for their valuable contributions over many years.

References (67)

  • E. Beutler et al.

    Mutation analysis in hereditary hemochromatosis

    Blood Cells Mol Dis

    (1996)
  • J.C. Barton et al.

    Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis

    Blood Cells Mol Dis

    (1997)
  • J.T. Salonen et al.

    High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men

    Circulation

    (1992)
  • J.T. Salonen et al.

    Body iron stores and the risk of coronary heart disease [Letter]

    N Engl J Med

    (1994)
  • M.K. Magnusson et al.

    Low iron-binding capacity as a risk factor for myocardial infarction

    Circulation

    (1994)
  • M.J. Stampfer et al.

    A prospective study of plasma ferritin and risk of myocardial infarction in US physicians [Abstract]

    Circulation

    (1993)
  • M. Mänttäri et al.

    Serum ferritin and ceruloplasmin as coronary risk factors

    Eur Heart J

    (1994)
  • G.H. Frey et al.

    Serum ferritin and myocardial infarct

    W V Med J

    (1994)
  • C.T. Sempos et al.

    Body iron stores and the risk of coronary heart disease

    N Engl J Med

    (1994)
  • Y. Liao et al.

    Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study

    Am J Epidemiol

    (1994)
  • D.M. Baer et al.

    Iron stores are not associated with acute myocardial infarction

    Circulation

    (1994)
  • A. Reunanen et al.

    Body iron stores, dietary iron intake and coronary heart disease mortality

    J Intern Med

    (1995)
  • I.A. Van Asperen et al.

    Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women

    Int J Epidemiol

    (1995)
  • H.I. Morrison et al.

    Serum iron and rick of fatal acute myocardial infarction

    Epidemiology

    (1994)
  • C.T. Sempos et al.

    Iron and heart disease: the epidemiologic data

    Nutr Rev

    (1996)
  • M. Moore et al.

    No association between serum ferritin and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study

    Am J Epidemiol

    (1995)
  • D.G. Meyers

    The iron hypothesis-does iron cause atherosclerosis?

    Clin Cardiol

    (1996)
  • J.M. McCord

    Effects of positive iron status at a cellular level

    Nutr Rev

    (1996)
  • J.M. McCord

    Is iron sufficiency a risk factor in ischemic heart disease?

    Circulation

    (1991)
  • C. Smith et al.

    Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions

    Biochem J

    (1992)
  • D. Steinberg et al.

    Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity

    N Engl J Med

    (1989)
  • J.S. Beckman et al.

    Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide

    Proc Natl Acad Sci USA

    (1990)
  • M. Saran et al.

    Reaction of NO with O2. Implications for the action of endothelium-derived relaxing factor (EDRF)

    Free Radic Res Commun

    (1990)
  • Cited by (117)

    • Water pollution in rural areas: Primary sources and associated health issues

      2023, Water Resources Management for Rural Development: Challenges and Mitigation
    • Meta-analyses of HFE variants in coronary heart disease

      2013, Gene
      Citation Excerpt :

      A total of 21 studies between HFE gene variants and the risk of CHD were retrieved from the online databases. Four studies (Adams et al., 2009; Hetet et al., 2001; Larsen et al., 2002; Rasmussen et al., 2001) were excluded due to a lack of genotype or allele information. Other two studies (Dunn et al., 2008; Pardo Silva et al., 2010) were excluded because their studies were not designed as a case–control study, cross-sectional study or prospective study.

    • The genetic landscape of hereditary haemochromatosis

      2023, Genetic Disorders and Rare Diseases: Current Updates
    View all citing articles on Scopus
    View full text